- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02743338
CompRest - a Comparison Between Sleep Compression and Sleep Restriction for Treating Insomnia (CompRest)
CompRest - a Randomized Comparison Between Sleep Compression and Sleep Restriction for the Treatment of Insomnia
This study includes two consecutive sub-trials.
Cognitive Behavioral Therapy (CBT) is treatment of choice for Insomnia. One of the most important treatment Components in CBT for insomnia (CBT-i) is Sleep Restriction (SR), but lately, adverse effects related to SR have been reported. A treatment method with similarities to SR is Sleep Compression (SC). SC is not as well studied as SR, but appears to have similar effects to SR but without the adverse effects. The first sub-trial thus aims at directly comparing SR and SC. The second sub-trial aims at evaluating any additional effects of CBT-i components given as an add-on treatment to a randomized selection of half participants in each original treatment arm.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 14186
- Internetpsykiatrienheten (Internet Psychiatry Clinic) Psykiatri Sydväst, SLSO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical level of Insomnia (more than 10 on ISI)
- Meets criteria for Insomnia Disorder according to DSM-V
- Sufficient language skills
- Having access to Internet to fill out forms and participating in treatment
- Not foresee obstacles to participating in treatment during the coming 20 weeks, or participating in measurements during the coming year.
Exclusion Criteria:
- Sleep disorders requiring other treatment
- High consumption of alcohol/drugs that affect sleep
- Somatic or psychiatric conditions counter-indicative of treatments given in the study, requiring acute care, or with symptoms and level of functioning affecting the ability to participate in the treatment programs.
- Working (night) shifts
- Ongoing psychological treatment for Insomnia with sleep restriction or sleep compression as a treatment component - also previous such treatment can be excluding
- Use of sleep medication in such a way that may hinder the implementation of the methods in this treatment
- Pre-treatment measurements not finished within the given time-frame.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sleep Restriction followed by additional CBT-i components
Sleep Restriction treatment during 5+5 weeks.
Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
|
Behavioral component of CBT-i.
Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached.
The first five weeks, therapist support is provided via written messages.
The next five weeks, patient works independently.
At the end of tenth treatment week, therapist and patient make plan for future.
After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support.
Component allocation based on individual analysis.
|
|
Active Comparator: Sleep Compression followed by additional CBT-i components
Sleep Compression treatment during 5+5 weeks.
Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
|
After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support.
Component allocation based on individual analysis.
Behavioral component of CBT-i.
Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached.
The first five weeks, therapist support is provided via written messages.
The next five weeks, patient works independently.
At the end of tenth treatment week, therapist and patient make plan for future.
|
|
Active Comparator: Sleep Restriction followed by no intervention
Sleep Restriction treatment during 5+5 weeks.
Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
|
Behavioral component of CBT-i.
Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached.
The first five weeks, therapist support is provided via written messages.
The next five weeks, patient works independently.
At the end of tenth treatment week, therapist and patient make plan for future.
|
|
Active Comparator: Sleep Compression followed by no intervention
Sleep Compression treatment during 5+5 weeks.
Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
|
Behavioral component of CBT-i.
Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached.
The first five weeks, therapist support is provided via written messages.
The next five weeks, patient works independently.
At the end of tenth treatment week, therapist and patient make plan for future.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Severity Index (ISI)
Time Frame: Change from base-line to 5 weeks, 10 weeks, 20 weeks and 57 weeks
|
7-item, self-rated questionnaire measuring change in insomnia severity.
Bastien, C. H., Vallières, A., & Morin, C. M. (2001).
Validation of the Insomnia Severity Index as an outcome measure for insomnia research.
Sleep Medicine, 2, 297-307.
|
Change from base-line to 5 weeks, 10 weeks, 20 weeks and 57 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep diary
Time Frame: Continuously from one week before treatment start (-1 week) to the last week of treatment (week 10)
|
Daily self-ratings on a number of sleep parameters, resulting in measures of sleep latency, total sleep time, sleep efficacy, number of nighttime awakenings, subjective sleep quality and daytime functioning
|
Continuously from one week before treatment start (-1 week) to the last week of treatment (week 10)
|
|
Actigraphy
Time Frame: Continuously from one week before treatment start (-1 week) to the last week of treatment (week 10)
|
An actigraph is placed on the participant's arm for one week.
They measure participants' activity in the form of movements.
It will be used for acquiring sleep data and calculate sleep latency, total sleep time, sleep efficacy, number of nighttime awakenings and daytime activity
|
Continuously from one week before treatment start (-1 week) to the last week of treatment (week 10)
|
|
Adverse Events
Time Frame: Week 2, week 4 and week 5
|
Self-report questionnaires and interviews
|
Week 2, week 4 and week 5
|
|
Sleep Problems Acceptance Questionnaire
Time Frame: Change from base-line to 5 weeks, 10 weeks, 20 weeks and 57 weeks
|
Change from base-line to 5 weeks, 10 weeks, 20 weeks and 57 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Polysomnography
Time Frame: One week before treatment (Week -1) and at week 1, week 3, week 5, and week 10
|
Ambulatory objective sleep stage and sleep timing measure
|
One week before treatment (Week -1) and at week 1, week 3, week 5, and week 10
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016/44-31/4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Christoph NissenRecruitingInsomnia | Insomnia Chronic | Insomnia Disorder | Insomnia, Primary | Insomnia Type; Sleep Disorder | Insomnia Disorders | Insomnia, NonorganicSwitzerland
-
University of PennsylvaniaPatient-Centered Outcomes Research InstituteRecruitingInsomnia | Chronic Insomnia | Insomnia Disorder | Chronic Insomnia DisorderUnited States
-
Shanghai Haiyan Pharmaceutical Technology Co.,...Completed
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
Clinical Trials on Sleep Restriction
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Associação Fundo de Incentivo...Completed
-
Lance BollingerNational Aeronautics and Space Administration (NASA)CompletedMuscle Weakness | Sleep Disturbance | Quadriceps Muscle AtrophyUnited States
-
Esther WerthCompletedIdiopathic Hypersomnia | Narcolepsy 1Switzerland
-
University of ZurichFonds für Verkehrssicherheit FVSCompletedSleep Deprivation | Sleepiness | Insufficient Sleep SyndromeSwitzerland
-
University of Missouri-ColumbiaRecruiting
-
University School of Physical Education, Krakow...Jagiellonian UniversityRecruitingSleep | Sleep RestrictionPoland
-
Oregon Health and Science UniversityRecruitingObesity | Glucose Intolerance | Sleep Deprivation | Weight Gain | Food SelectionUnited States
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of ChicagoCompleted
-
Institut de Recherche Biomedicale des ArmeesCompleted